Title: The Application of Radiomics in Laryngeal Cancer

Shortened Title: Radiomics & Laryngeal Cancer

Authors: Amarkumar Dhirajlal Rajgor\(^{1, 2, 3}\) (corresponding author), Shreena Patel\(^4\), David McCulloch\(^5\), Boguslaw Obara\(^6\), Jaume Bacardit\(^6\), Andrew McQueen\(^5\), Eric Aboagye\(^7\), Tamir Ali\(^5\), James O’Hara\(^{1, 2}\), David Winston Hamilton\(^{1, 2}\)

Affiliations:
\(^1\) Otolaryngology Department, Newcastle-Upon-Tyne Hospitals NHS Foundation Trust, Freeman Road, Newcastle-Upon-Tyne, UK, NE7 7DN
\(^2\) Applied Cancer Therapeutics and Outcomes, Newcastle University, Newcastle-Upon-Tyne, UK NE1 7RU
\(^3\) National Institute for Health Research, Academic Clinical Fellow
\(^4\) East of England NHS Foundation Trainee, Dunstable, Bedfordshire, UK, LU6 1JJ
\(^5\) Radiology Department, Newcastle-Upon-Tyne Hospitals NHS Foundation Trust, Freeman Road, Newcastle-Upon-Tyne, UK, NE7 7DN
\(^6\) School of Computing, Newcastle University, Urban Sciences Building, 1 Science Square, Newcastle Helix, Newcastle upon Tyne, NE4 5TG, UK
\(^7\) Imperial College London Cancer Imaging Centre, Department of Surgery & Cancer, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK

Correspondence Address:
Mr Amarkumar Rajgor, Newcastle-Upon-Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, NE7 7DN
Email: amar.rajgor@nhs.net
Telephone: 07925020835

Keywords:
Laryngeal cancer; radiomics; artificial intelligence; head & neck cancer;

Declaration of Interests
We declare no competing Interests.

Author Contributions
AR, DH, EA, BO developed the concept of this review. Titles and abstracts were screened by two researchers (AR and SP). Full text screening for eligibility was done by two reviewers (AR and SP). AR quality appraised studies and produced the tables and the figure. AR wrote the first draft of the manuscript with input from all authors. All authors contributed to drafting and editing the manuscript.

Additional Information
AR is a National Institute for Health Research Academic Clinical Fellow. There was no funding source for this review.
Abstract

Background: Radiomics is the conversion of medical images into quantitative high-dimensional data. Laryngeal cancer, the most common head and neck cancer, has risen globally by 58.7%. CT, MRI and PET are acquired during the diagnostic process providing potential data for radiomic analysis and correlation with outcomes.

Objectives: This review aims to examine the applications of this technique to laryngeal cancer and the future considerations for translation into clinical practice.

Methods: A comprehensive systematic review-informed search of the MEDLINE and EMBASE databases was undertaken. Keywords ‘laryngeal cancer’ OR ‘larynx’ OR ‘larynx cancer’ OR ‘head and neck cancer’ were combined with ‘radiomic’ OR ‘signature’ OR ‘machine learning’ OR ‘artificial intelligence’. Additional articles were obtained from bibliographies using the ‘snowball method’.

Results: The included studies (n=17) demonstrated that radiomic features are significantly associated with various clinical outcomes (including stage, overall survival, treatment response, progression-free survival) and that predictive models incorporating radiomic features are superior to those that do not. Two studies demonstrated radiomics could improve laryngeal cancer staging whilst fourteen studies affirmed its predictive capability for clinical outcomes.

Conclusions: Radiomics has potential for improving multiple aspects of laryngeal cancer care, however, the heterogenous cohorts and lack of data on laryngeal cancer exclusively inhibits firm conclusions. Large prospective well-designed studies in laryngeal cancer are required to progress this field. Furthermore, to implement radiomics into clinical practice, a unified research effort is required to standardise radiomics practice.

Advances in knowledge: This review has highlighted the value of radiomics in enhancing laryngeal cancer care (including staging, prognosis and predicting treatment response).
Introduction

Since the 1990s, head and neck cancer (HNC) incidence rates have risen by 33% and it is now the sixth most common cancer worldwide. A large proportion of these cases occur in the larynx. Laryngeal cancers are staged according to the American Joint Committee on Cancer (AJCC) Tumour Node Metastases (TNM) system. Early-stage cancers incorporate T-stage 1 and 2 tumours whilst T-stage 3 and 4 are deemed advanced-stage cancers. Early stage disease has a 3-year disease-specific survival rate of 89% however advanced stage disease has a significantly worse survival rate of 50%. The uncertainty regarding the ideal treatment modality (surgery or chemoradiotherapy) for advanced laryngeal cancer is an important issue and to improve outcomes, personalised (tumour-specific) treatment plans are required. With the current available methods, it is a substantial challenge to predict which patients are likely to respond to a specific treatment modality. Therefore, creating robust clinical decision-making models incorporating all available data sources (including medical imaging) are crucial.

During the diagnostic and staging process for laryngeal cancer contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) are typically acquired. These images hold valuable information on the tumour and its surrounding microenvironment. Although historically, medical imaging had been solely interpreted subjectively by a clinician, with advances in computational algorithms it is now possible to extract quantitative (objective) information such as tumour shape, size, texture and intensity from such images in a reproducible and robust manner. These data can be analysed and correlated with clinical outcomes. This process of image conversion into mineable high dimensional data is known as radiomics. The radiomics workflow involves four key steps image acquisition, tumour segmentation, feature extraction and subsequent analysis resulting in a radiomic-based model. Furthermore, biopsies for laryngeal cancer are restricted since samples are obtained from one anatomical site of the tumour at a single time point whilst the patient is under general anaesthetic. However, radiomics provides a non-invasive method of evaluating the whole tumour over-time.

To date, radiomics has shown great promise in various specialties and diseases. In lung cancer radiomic techniques can accurately predict the cancer status (malignant or benign) of pulmonary nodules, the histological subtype of lung cancers, and predict both survival and response to (chemo)radiotherapy. In oesophageal cancer radiomics based models can identify the stage of oesophageal squamous cell carcinomas, predict treatment response and prognosis. The correlation with gene expression profiles have been demonstrated in multiple cancer sites.

Despite this growing body of evidence, to our knowledge there is no study that has critically reviewed the value of radiomics in laryngeal cancer. Thus, this narrative review aims to evaluate the applications of radiomics in laryngeal cancer to date, highlight the limitations and the potential future uses.

Methods

Search strategy and selection criteria
A comprehensive systematic-review informed search of the Ovid MEDLINE and EMBASE online databases (no interval/period stipulated) was undertaken in November 2020. Keywords ‘laryngeal cancer’ OR ‘larynx’ OR ‘larynx cancer’ OR ‘head and neck cancer’ were combined with ‘radiomic’ OR ‘signature’ OR ‘machine learning’ OR ‘artificial intelligence’. This resulted in 889 publications. Subsequently duplicates were removed, abstracts were screened for relevance and only full peer-reviewed articles in the English language were included. Additional articles were obtained from bibliographies using the ‘snowball method.’ Two independent reviewers conducted the search and screened the quality of the articles for inclusion. Discrepancies were resolved by consensus. All peer-reviewed articles incorporating radiomic analysis of patients with laryngeal cancer were included. This resulted in 17 articles (Figure 1). We synthesised study findings narratively.

Results

Through our structured search we identified 997 records, of which 17 studies met the inclusion criteria. Findings from the included studies are detailed below in three sections; the use of radiomics in laryngeal cancer staging (Table 1), the predictive value of CT-based radiomics (Table 2) and the predictive value of PET-based radiomics in laryngeal cancer (Table 3).

Radiomics in laryngeal cancer staging

Two studies were identified from the indexed literature (summarised in Table 1). Guo et al evaluated the use of CT-based radiomics to predict thyroid cartilage invasion from squamous cell carcinomas (SCC) of the larynx and hypopharynx. In this patient cohort (n=236), 80 had evidence of thyroid cartilage invasion (confirmed by histopathological assessment). The authors demonstrated that a radiomics-based model had greater capability than a radiologist alone in determining thyroid cartilage invasion from CT imaging. The model performance was assessed by the area under the receiver operator curve (AUC). The AUC is a measure of the accuracy of a model. A value <0.5 is deemed as no better accuracy than chance, whilst a value with a perfect accuracy is 1. The AUCs for predicting thyroid cartilage invasion were 0.905 (95%CI, 0.863-0.937), 0.876 (95% CI: 0.830-0.913) for the two radiomics-based models and 0.721 (95%CI, 0.663–0.774) for the radiologist alone. This study was limited due to its use of three different scanners (with different scanning parameters) and tumour demarcation was conducted by two junior radiologists, which may result in inaccurate segmentation.

Wang et al assessed the value of CT-radiomics in distinguishing between T3 and T4 tumours, since surgical decision-making is often influenced by this distinction. 211 patients with locally advanced laryngeal cancer who underwent a total laryngectomy were included. Eight radiomic features were associated with the T-stage. Three models were subsequently formed and assessed for their predictive capability of T-stage (as determined by histopathological assessment following total laryngectomy); a radiologist alone, a radiomics signature and a nomogram (a pictorial representation of a complex mathematical model that generates a probability of an event combining both. The AUCs were 0.775 (95%CI, 0.667–0.883), 0.862 (95% CI: 0.772–0.952) and 0.892 (95% CI: 0.811–0.974) for the radiologist alone, the radiomics signature and a combination of radiology reporting and the radiomics signature, respectively. The main limitations of this study are it was a single-centre retrospective study and the CT imaging analysed may have been taken some time
Predictive value of radiomics in laryngeal cancer

Overall, there is limited literature on the value of predictive radiomics exclusively in laryngeal cancer. However, studies have been conducted in HNCs, which incorporate a sub-cohort of laryngeal cancer patients. Detailed below are studies evaluating the predictive capability of CT and PET based radiomics.

Predictive value of computed tomography based radiomics

Ten studies were included from that evaluated the predictive value of CT-based radiomics (summarised in Table 2). Chen et al\(^2\) used LIFEx radiomics software to analyse CT imaging of 96 laryngeal cancer patients. They subsequently generated a radiomics nomogram incorporating three radiomic textural features (high gray-level run emphasis, long-run high gray-level emphasis and zone length non-uniformity) and clinicopathological outcomes. The predictive capability of the model was assessed by the concordance index (C-index). The C-index provides a goodness of fit statistic for a predictive model whilst accounting for censored data. Therefore, it is often used to evaluate predictive models for survival. Similar to AUC, a value <0.5 suggests a poor model whilst a value closer to 1 suggests a strong model. The radiomics nomogram had better prognostic capability (overall survival - OS) than cancer staging alone (C-index, 0.817 vs. 0.682, \(p=0.009\)) and demonstrated good agreement between actual and predicted survival. However, this retrospective study conducted in a single centre included a relatively small population, with potential selection bias. Although the training and validation cohorts were similar, the treatment received, and complications of treatment could also be potential confounders.

Agarwal et al\(^2\), analysed pre-treatment imaging of advanced laryngopharyngeal SCC (\(n=31\)) treated with chemoradiotherapy and demonstrated that medium texture entropy was an independent predictor of local control (\(p<0.001\)) and laryngectomy-free-survival (\(p<0.001\)). This study had numerous strengths; firstly, the patient cohort was uniformly treated with chemoradiotherapy unlike other studies which have an array of different treatment approaches. Furthermore, all images were obtained using a uniform protocol from the same CT scanner. However, the tumour was contoured by a single operator thus cannot account for inter-operator variability. Also, the tumour was delineated at the point of maximal cross-sectional area, meaning that the entire tumour was not analysed; although this may be less time-consuming if implemented into clinical practice.

In the indexed literature, eight further studies evaluating CT-radiomics were identified that incorporated a sub-cohort of laryngeal cancer patients. Ou D\(^2\) et al analysed pre-treatment images of patients with locally advanced HNCs treated with chemoradiotherapy (cisplatin with radiotherapy) or bio-radiotherapy (cetuximab with radiotherapy). 18 of 120 patients included in the study had laryngeal cancer. Multivariate analysis showed a radiomic signature (incorporating 24 radiomic features) significantly predicted OS (HR 0.3, \(p=0.02\)) and progression-free survival (PFS) (HR 0.3, \(p=0.02\)). Further combination with the molecular phenotype (p16 status) created an enhanced predictive model (AUC = 0.78 vs AUC = 0.67, \(p=0.01\)) for overall survival. This study highlights the utility of a multitude of
data sources such as clinical staging, risk factors for disease, radiomic features and molecular phenotypes to form robust predictive models. However, this retrospective study included a small heterogeneous population (primary tumours of distinct anatomical subsites) and during the study period the standard of care for CT acquisition changed which could impact the validity of the results. Furthermore, the implementation of the p16 status into the model has limited value in laryngeal cancer since this is of prognostic importance in oropharyngeal cancers.

Zhang et al, incorporating 21 patients with laryngeal cancer, evaluated the association of CT radiomics with survival in HNC patients treated with induction chemotherapy (cisplatin, 5-fluorouracil, docetaxel)\textsuperscript{28}. The authors identified primary mass entropy (HR 2.10, \(p=0.036\)) and skewness measurements (HR 3.67, \(p=0.009\)) as independent predictors of overall survival. There were multiple limitations in this retrospective study including a small heterogenous patient population, lack of validation in an external cohort, exclusion of non-contrast CT imaging which excludes patients with renal impairment and only a single user performed the segmentation. Kuno et al\textsuperscript{29} also demonstrated that numerous textural features including three histogram features (geometric mean [HR 4.68, \(p=0.026\)], harmonic mean [HR 8.61, \(p=0.004\)], and fourth moment [HR 4.56, \(p=0.048\)]) and four gray-level run-length features (short-run emphasis [HR 3.75, \(p=0.044\)], gray-level nonuniformity [HR 5.72, \(p=0.004\)], run-length nonuniformity [HR 4.15, \(p=0.043\]), and short-run low gray-level emphasis [HR 5.94, \(p=0.035\)]) were associated with local treatment failure in HNSCC (19/62 patients with laryngeal cancer). However, the study included a heterogeneous population, with differing CT protocols, slice thickness and exclusion of regions demonstrating necrosis and ulceration. Cozzi et al also confirmed that CT-based radiomic features correlated well with overall survival (Run length Non-Uniformity, Gray-Level Non-Uniformity, Neighbourhood Gray-Level Different Matrix (NGLDM) Coarseness), PFS (Shape Compacity, Gray-Level Co-occurrence Matrix (GLCM) Correlation) and local control (Shape Volume, NGLDM Coarseness) in HNC patients (8/110 with laryngeal cancer) treated with chemoradiotherapy\textsuperscript{30}. Although CT acquisition parameters were uniform, limitations include the study’s retrospective nature, inclusion of a heterogeneous population from a single centre, lack of external validation and segmentation by one radiation oncologist.

Bogowicz et al analysed CT imaging of HNSCC patients (of which 4 had laryngeal cancer) and produced a radiomic signature (composed of 3 radiomic features - HHH large zone high gray-level emphasis, LLL sum entropy, and LLH difference variance) that could predict local tumour control (with a concordance index (C-index) of 0.78)\textsuperscript{31}. This study also created another radiomics signature which could accurately predict HPV status from CT imaging (AUC 0.85). However, the study is limited by the use of three scanners, with differing protocols in a single institution. Meneghetti et al\textsuperscript{32} both, developed and validated a radiomics signature incorporating two significant radiomic features (High-dependence high-emphasis of the NGLDM and 10\textsuperscript{th} percentile of histogram intensity) locoregional control in advanced HNSCC. This model achieved good discriminatory performance when performed on an external validation cohort (C-Index 0.66, 95%CI 0.55–0.75). However as with a lot of these studies there were a limited sub-cohort of laryngeal cancer patients, only 8 of 233, to draw conclusions regarding laryngeal cancer.
Vallières et al conducted one of the largest studies to date, and extracted 1615 radiomic features from pre-treatment CT and PET images of 300 patients (45 with laryngeal cancer) to correlate with the risk of locoregional recurrence and distant metastases in HNCs. The prediction models formulated (combining both clinical and radiomic features) were good predictors of locoregional control (AUC 0.69, C-Index 0.67) and distant metastases (AUC 0.86, C-Index 0.88). This study had numerous strengths, in particular that patient recruitment was undertaken at multiple sites and the combination of PET and CT based radiomics.

Finally, Keek et al identified that CT-based radiomic features extracted from peri-tumoural tissue (surrounding microenvironment) from HNSCCs were not useful in the prediction of locoregional recurrence or distant metastasis. This study incorporated 57 (of 444) patients with laryngeal cancer. Although Keek et al used an external validation dataset, this study was limited due to its retrospective nature, leading to a several clinical features (such as weight loss) not being comparable between the training and validation cohorts and the omission of valuable semantic imaging.

**Predictive value of positron emission tomography based radiomics**

Alongside CT, PET imaging with fluorodeoxyglucose (18F-FDG) provides useful functional and metabolic information on a tumour. As such, PETCT has been targeted for radiomic analysis. Although to date, there are no studies that evaluate PET radiomics exclusively in laryngeal cancer, five studies were identified from the literature that include a subcohort of laryngeal cancer patients (summarised in Table 3).

Guezennec et al identified metabolic tumour volume ($p=0.008$) and the textural feature correlation ($p=0.028$) obtained from 18F-FDG PET in HNCs were prognostic factors for overall survival. Of the 284 patients included, 32 patients had laryngeal cancer. There are several limitations in this study including analysis of a heterogeneous cohort of patients with tumours of differing anatomical subsites and staging and in 99 patients, due to very small regions of interest, they were unable to extract radiomic features. Feliciani G et al used PET radiomics to predict treatment failure in HNCs treated with chemoradiotherapy. 14 (of 90) patients had laryngeal cancer and retrospective radiomic analysis identified a lower Low-intensity Long-run Emphasis (LILRE) was associated with greater risk of treatment failure. Additionally, the model based on radiomics markers was superior in predicting local failure compared to the model based on clinical variables alone (C-index 0.76 vs 0.65).

Bogowicz et al also conducted two studies to determine the benefits of 18F-FDG PET radiomics in head and neck cancer. In one study they extracted radiomic features using two different ‘in-house’ radiomics software packages from images three months post-radiotherapy. The aim was to predict tumour control and determine whether the radiomics software used had a substantial impact. 11 of 128 patients had laryngeal cancer, and the authors demonstrated that radiomic features histogram range and GLCM difference entropy were associated with local control and both models (from differing software) performed equally well (with C-indices >0.7 in all models). This emphasises that different software implementations can be equally valuable. Their second study compared the use of 18F-FDG PET to CT radiomics for patients with
This study included 10 (of 121) patients with laryngeal cancer. The model demonstrated that more homogenous tumours (Gray-Level Size Zone Matrix (GLSZM) entropy) with a focused region of high FDG uptake (GLSZM Short-Zone Low Gray-level Emphasis) suggested a better prognosis. Both PET, CT and PET/CT (combined) based models performed equally well in predicting local tumour control with C-indices of 0.72, 0.74, 0.77 respectively. This study has certain limitations including its retrospective nature, the lack of external validation and patients were recruited from a single centre potentially resulting in selection bias. Furthermore, it is well-known that not the entire tumour exhibits increased metabolic activity, therefore areas of the tumour may have been missed through the auto-segmentation process.

The final study, assessing PET radiomics was conducted by Ulrich EJ et al. The authors undertook radiomic analysis of baseline 18Fluorothymidine-based (marker of proliferation) PET imaging to determine treatment response in HNCs (n=30). The study identified nine radiomic features (see table 3) that were significantly associated with PFS. These results implied smaller and more homogenous tumours had the best prognosis. However, in the context of laryngeal cancer this study is limited by small sample size (n=2). In addition, the effects of repeated scans and image reconstruction parameters on FLT-based radiomic features has not been determined.

Discussion

This review has demonstrated that radiomic features extracted from CT and PET imaging can help in predicting treatment response, molecular phenotypes, prognosis and assist in the staging process for laryngeal cancer. 16 of the 17 studies showed that radiomic features are significantly associated with various outcomes (including OS, treatment response, PFS) and that predictive models incorporating radiomic features are superior to models that exclude radiomics. Despite these promising findings, the lack of studies evaluating laryngeal cancer exclusively means drawing valid conclusions is challenging. Further large collaborative multicentre prospective studies exclusive to laryngeal cancer are required to progress this field.

Laryngeal cancer staging

Accurate pre-therapeutic staging of laryngeal carcinomas is an important factor in guiding treatment. There are often discrepancies between the clinical stage (clinical examination with imaging) and the pathological stage (based on the pathology specimen), which can result in inadequate or excessive treatment. There are two key challenges regarding laryngeal cancer staging that need to be addressed. Firstly, the distinction between T2 and T3 tumours because current guidelines advise different treatment options. Due to its excellent soft tissue resolution, MRI imaging is often used to aid in this distinction as it can delineate cartilage involvement and deep tumour extension. T2 tumours are advised microsurgery or radiotherapy, whilst T3 tumours are recommended chemoradiotherapy or surgery with adjuvant (chemo)radiotherapy. The second challenge is the distinction between T3 and T4 tumours, which is predominantly based on the extent of extra-laryngeal spread and/or destruction of the thyroid cartilage. This distinction is crucial in deciding between chemoradiotherapy or a total laryngectomy.
Thus, it is important to identify additional methods to stage the cancer correctly as this could have a significant impact on a patient's outcome.

There are two studies detailed in the results (Guo et al, Wang et al) which focus on advanced laryngeal cancer and show the benefits of radiomics in predicting thyroid cartilage invasion and distinguishing between T3 and T4 tumours. Clinically, accurate assessment of cartilage invasion is essential as this will influence the treatment strategy. Firstly, invasion of the inner cortex of the thyroid cartilage suggests T3 disease, which has a differing treatment approach relative to T2 tumours. Furthermore, invasion through the thyroid cartilage would suggest T4 disease and would thus meet criteria for a potential laryngectomy. To date, no studies have sought to use radiomics to tackle the challenge of early stage disease (i.e. the distinction between T2 and T3). Further large-scale studies addressing the challenges of staging are required.

Predictive value of radiomics in laryngeal cancer

Of the fifteen studies evaluating the predictive value of radiomics only one study (Chen et al) focussed exclusively on laryngeal cancer. The authors demonstrated that a radiomics-based model incorporating three radiomic features and clinicopathological features (tumour stage, anatomical subsite, laryngectomy) had good predictive capability for OS. In fact, 14 of the 15 studies demonstrated that including radiomic features significantly improves prediction models for various outcomes. However, this may be due to publication bias, where negative results have not been published. Only one study, conducted by Keek et al, highlighted that radiomic features were not useful, although this study did evaluate peri-tumoural tissue rather than the entire tumour. Although these results show promise it is important to highlight that the majority of studies include heterogenous cohorts of patients with an array of different HNCs of distinct anatomical subsites at various stages. Thus, further studies are required before extrapolating these findings to laryngeal cancer.

A key focus in laryngeal cancer should be the formation of robust prediction models to aid in stratifying patients more likely to respond to specific treatments. Radiomics alone is not a solution for these models but if combined with other key clinicopathological features (such as demographics, risk factors for disease, histopathological features and genomic structure) can form robust clinical decision-making models.

 Limitations of Literature

There are several limitations that resonate throughout the literature and should be addressed in future studies. Firstly, the majority of these studies have been conducted in single centres and have failed to validate their findings externally. They also include heterogenous cohorts with an array of different HNCs with laryngeal cancer generally poorly represented. Secondly, the use of different scanners with different scanning parameters and different protocols also limits the literature. The radiomic software implementations ranged from in-house developed software to readily available free software (e.g. LIFEx) (as seen in Table 2). The reliability and prognostic value of radiomic features can be highly dependent.
on the platform used, thus making this process coherent and unified is a significant challenge. Although the image biomarker standardisation initiative (an international collaboration) is making strides in standardising this process. In addition, radiomic contouring was often conducted by a single operator and thus could not account for inter-observer variability and has greater potential for human error.

Finally, the lack of biological and genomic data to allow correlation with radiomic features. Correlation will improve our understanding of specific radiomic features and how they reflect tumour biology.

Future Considerations
Radiomics has significant promise but further developments are required before translation from bench to bedside. Firstly, the level of evidence regarding laryngeal cancer is insufficient and large multicentre prospective studies exclusively in laryngeal cancer are required. A consensus also needs to be reached regarding scanning protocols, image segmentation and feature extraction software. In the future, deep learning techniques could also be implemented to perform its own implicit feature extraction. Finally, to improve reproducibility, publications should allow access to raw data, and methods used to extract features.

The strengths of this review include the comprehensive search strategy and the screening process using two independent reviewers. Furthermore, the pitfalls that resonate throughout the literature have been highlighted. These can act as a guide for researchers formulating new studies to ensure these are addressed. However, there are some limitations. The lack of studies exclusively on laryngeal cancer, the use of different software implementations and the use of different scanning parameters means drawing meaningful conclusions is difficult. Finally, our review was limited to studies in the English language.

Conclusion
This review highlights that radiomics has great potential for improving multiple aspects of laryngeal cancer care from staging, prognosis to predicting treatment response. By evaluating the current literature this review provides a stepping stone for the future integration of radiomics in laryngeal cancer care.

However, the lack of data on laryngeal cancer exclusively means drawing conclusions is challenging. Further large prospective studies exclusively in laryngeal cancer, utilising genomic and biological data are required to progress this field. In order to implement radiomics into clinical practice a unified research effort is required to standardise radiomic practice.
Figure 1: PRISMA flow diagram of the literature review process for studies on the application of radiomics in laryngeal cancer
<table>
<thead>
<tr>
<th>Author</th>
<th>Radiomics Software Used</th>
<th>Image Modality</th>
<th>Study Objective</th>
<th>Total Number of Laryngeal Cancer Patients (n)</th>
<th>Primary Treatment</th>
<th>Model Evaluation</th>
<th>Significant Radiomic Features</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang F et al** [2019]</td>
<td>Pyradiomics</td>
<td>CT</td>
<td>Determine whether CT radiomics could enhance the accuracy of T-staging in advanced laryngeal cancer</td>
<td>211 [TC: 150] [VC: 61]</td>
<td>Surgery</td>
<td>Single Institute Cohort divided into training and validation cohorts</td>
<td>Associated with T-Stage: 1) First order features: Skewness, 2D First Order Mean 2) Shape features: Least Axis Length, Sphericity 3) Wavelet features*: LLH - First order Kurtosis, LLH - GLCM IDN, LLH First Order Median, LLL GLCM IMC</td>
<td>Developed a nomogram (combining the radiomic signature and T-stage reported by radiologists) with good accuracy (AUC: 0.892, 95% CI: 0.811–0.974) for T-staging.</td>
</tr>
<tr>
<td>Guo R et al [2020]</td>
<td>Radcloud Platform &amp; Anaconda3 platform</td>
<td>CT</td>
<td>Determine whether CT radiomics could aid in the prediction of thyroid cartilage invasion from laryngeal and hypopharyngeal cancer</td>
<td>236</td>
<td>Surgery</td>
<td>Single Institute 5-fold Cross-Validation</td>
<td>4 shape features 7 first order features 5 GLRLM associated features 4 GLCM features 3 GLSZM features</td>
<td>The Radiomics-based models (AUC 0.905, 95%CI 0.863–0.937) were more accurate than a clinical radiologist alone (0.721, 95%CI: 0.663–0.774) in predicting thyroid cartilage invasion</td>
</tr>
</tbody>
</table>

*For wavelets where L and H are low- and high-frequency signals, respectively.

** Study evaluates laryngeal cancer patients exclusively.

Abbreviations: CT – Computed Tomography, TR - Training cohort VC – Validation Cohort GLCM – Gray Level Co-occurrence Matrix, IDN - Inverse Difference Normalized, IMC – Informational Measure of Correlation, AUC – Area Under Curve, GLRLM – Gray Level Run-Length Matrix, GLSZM – Gray Level Size Zone Matrix

Table 1: Summary of literature on the value of radiomics in the accuracy of staging for laryngeal cancer
locally advanced laryngopharyngeal SCC with regards to local control and laryngectomy-free-survival.

1) Laryngectomy-free survival: Medium texture entropy, kurtosis, skewness, standard deviation

2) Local Control: Medium texture entropy
Skewness

---

Ou D et al [2017] Oncoradiomics CT
Evaluate the value of radiomics in patients with locally advanced HNSCC treated with chemoradiotherapy or bio-radiotherapy
18 Chemoradiotherapy Bio-radiotherapy 10-fold cross validation in single institute
Intensity features: 3 Shape features: 6 Texture features: 1 Wavelet features: 15

1) Radiomic features from CT imaging adds value as predictive biomarkers of head and neck cancers treated with chemoradiotherapy or bioradiotherapy.

2) Combination of radiomic features with p16 status allows further stratification into high and low risk groups in terms of overall survival

---

Zhang H et al [2013] TexRad CT
Evaluate whether CT-radiomics is associated with overall survival in patients with locally advanced HNSCC previously treated with induction chemotherapy
21 Induction Chemotherapy (cisplatin/5-FU/docetaxel) Nil Primary mass entropy Skewness

Independent of size, N-stage, and other clinical variables, primary tumour mass texture analysis features mass entropy & skewness are associated with overall survival in patients treated with induction chemotherapy

---

Kuno H et al [2017] In-house developed radiomics software (MATLAB)
Assess the value of radiomic textural features obtained from pre-treatment CT imaging of patients with HNSCC treated with chemoradiotherapy
19 Radiotherapy Chemoradiotherapy Nil

3 histogram features: Geometric mean, Harmonic mean, Fourth moment.

4 GLRLM features: SRE, GLNU, RLNU, and SRLGE

Following adjustment for clinical variables, 3 histogram and 4 GLRLM were associated with local failure in patients with HNSCC.
<table>
<thead>
<tr>
<th>Authors</th>
<th>Software</th>
<th>Imaging</th>
<th>Study Description</th>
<th>Methodology</th>
<th>Radiomic Features</th>
<th>Clinical Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cozzi L et al [2019]</td>
<td>LIFEx</td>
<td>CT</td>
<td>Evaluate the ability of a CT-based radiomics signature to predict clinical outcome following chemoradiotherapy in stage III-IV HNSCC</td>
<td>Chemoradiotherapy Nil</td>
<td>Radiomic Features predictive of: 1) Overall Survival: GLRLM RLNU, GLZLM GLNU, NGLDM Coarseness</td>
<td>CT-based radiomic features correlate well with overall survival, progression-free survival and local tumour control in head and neck cancer patients</td>
</tr>
<tr>
<td>Bogowicz M et al [2017]</td>
<td>In-house developed radiomics software (Python)</td>
<td>CT</td>
<td>Investigate the use of radiomics to predict local tumour control and HPV status in patients with HNSCC</td>
<td>Chemoradiotherapy Cohort from single institute divided into training and validation cohorts</td>
<td>HHH large zone high gray-level LLL sum entropy LLH difference variance</td>
<td>A radiomic signature composed of 3 significant features were associated with local control. This implies tumours with a less heterogeneous CT density distribution have better local control. HPV positive tumours have a homogenous CT distribution.</td>
</tr>
<tr>
<td>Meneghetti AR et al. [2020]</td>
<td>Medical Imaging Radiomics Processor (MIRP) Python package</td>
<td>CT</td>
<td>To develop and validate a CT-based radiomics signature for the prognosis of loco-regional tumour control in patients with HNSCC treated by primary chemoradiotherapy</td>
<td>Chemoradiotherapy 3-fold cross-validation across six partner sites</td>
<td>10th percentile of intensity histogram High-dependence high-emphasis of the NGLM</td>
<td>The final signature combined the tumour volume with two independent radiomics features and achieved moderately good discriminatory performance in determining locoregional control in a validation cohort.</td>
</tr>
<tr>
<td>Vallieres M et al [2017]</td>
<td>In-house developed radiomics software (MATLAB)</td>
<td>18F-FDG PET &amp; CT</td>
<td>Investigate the value of PET and CT imaging based radiomics in combination with clinical variables to formulate a prediction model for risk of recurrence in HNCs.</td>
<td>Radiotherapy Chemoradiotherapy Multi-centre cohort divided into training and validation cohorts</td>
<td>Radiomic feature with the highest association with: 1) Locoregional recurrence: LZHGE</td>
<td>Radiomics provide important prognostic information regarding locoregional recurrence and distant metastases in HNC.</td>
</tr>
</tbody>
</table>
2) Distant metastases: ZSN [GLSZM] (from CT imaging)
3) Overall survival: GLV [GLRLM] (from CT imaging).

Keek S et al. [2020] Oncoradiomics CT Investigate the use of CT-radiomics for prediction of overall survival, locoregional recurrence and distant metastases in advanced HNSCC peri-tumoural tissue treated with chemoradiotherapy. 57 Chemoradiotherapy Multi-centre cohort divided into training and validation cohorts - CT-based radiomic features obtained from peri-tumoural regions do not predict overall survival, locoregional recurrence and distant metastases

Table 2: Summary of literature on the prognostic and predictive value of CT-based radiomics in laryngeal cancer

** Study evaluates laryngeal cancer patients exclusively.


<table>
<thead>
<tr>
<th>Author</th>
<th>Radiomics Software Used</th>
<th>Image Modality</th>
<th>Primary Study Objective</th>
<th>Total number of Laryngeal Cancer Patients (n)</th>
<th>Primary Treatment</th>
<th>Model Evaluation</th>
<th>Significant Radiomic Features</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guezennec C et al [2018]</td>
<td>LIFEx</td>
<td>18F-FDG PET-CT</td>
<td>Evaluate the prognostic value of radiomic features extracted from pre-treatment 18F-FDG PET/CT images in HNSCC</td>
<td>32</td>
<td>Surgery Chemoradiotherapy Palliative Treatment Radiotherapy alone Chemotherapy alone</td>
<td>3D-fold cross-validation in single institute</td>
<td>MTV Correlation</td>
<td>MTV and 1 textural index extracted from pretherapeutic 18-F FDG-PET/CT (Correlation) were independent prognostic factors of overall survival in patients with HNSCC</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Software Details</td>
<td>Methodology</td>
<td>Purpose</td>
<td>Timepoint</td>
<td>Chemoradiotherapy</td>
<td>Validation</td>
<td>Institute</td>
<td>Additional Details</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------</td>
<td>-------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------</td>
<td>-----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Feliciani G et al. [2018]</td>
<td>CGITA v1.3</td>
<td>18F-FDG PET-CT</td>
<td>Evaluate the value of pre-treatment 18F-FDG PET radiomics for the prediction of treatment failure in primary HNSCC treated with concurrent chemoradiotherapy</td>
<td>14</td>
<td>Chemoradiotherapy</td>
<td>10-fold cross validation in single Institute</td>
<td>LILRE</td>
<td>Lower LILRE, is associated with higher local failure in patients with HNSCC treated with chemoradiotherapy</td>
</tr>
<tr>
<td>Bogowicz M et al. [2017]</td>
<td>In house developed radiomics software: 1) MAASTRO 2) University Hospital Zurich</td>
<td>18F-FDG PET-CT</td>
<td>Evaluate the association of post-chemoradiotherapy PET radiomics and local tumour control in HNSCC</td>
<td>11</td>
<td>Chemoradiotherapy</td>
<td>Cohort from single institute divided into training and validation cohorts</td>
<td>GLCM Difference Entropy. History Range</td>
<td>Higher histogram range and higher GLCM difference entropy corresponds to a greater risk of tumour recurrence. Both post-treatment PET-CT radiomic models were prognostic for local tumour control and performed equally well.</td>
</tr>
<tr>
<td>Bogowicz M et al. [2017]</td>
<td>In-house developed radiomics software (Python)</td>
<td>18F-FDG PET, CT</td>
<td>Investigate the value of pre-treatment 18F-FDG PET radiomics for determining local tumour control in HNSCC patients.</td>
<td>10</td>
<td>Chemoradiotherapy</td>
<td>5-fold cross validation in single Institute</td>
<td>CT: GLSZM entropy, HLH* intensity energy. PET: spherical disproportion, SZLGE [GLSZM]</td>
<td>Tumours more homogenous in CT density and with a focused region of high FDG uptake suggested a better prognosis. Both CT and PET radiomics showed equally good discriminative power for local tumour control in HNSCC.</td>
</tr>
<tr>
<td>Ulrich EJ et al. [2019]</td>
<td>Pyradiomics</td>
<td>18F-FLT PET</td>
<td>Evaluate the prognostic value of pre-treatment 18F-FLT PET imaging radiomics in predicting treatment response in HNSCC</td>
<td>2</td>
<td>Chemoradiotherapy</td>
<td>Nil</td>
<td>GLSZM GLNU GLRLM GLNU Spherical disproportion GLCM Correlation GLSZM Zone percentage Histogram Q1 distribution Volume</td>
<td>Smaller, more homogenous lesions at baseline were associated with a better prognosis.</td>
</tr>
</tbody>
</table>

Table 3: Summary of literature on the prognostic and predictive value of PET-based radiomics in laryngeal cancer

*For wavelets where L and H are low- and high-frequency signals, respectively.


Feliciani G, Fioroni F, Grassi E et al. Radiomic Profiling of Head and Neck Cancer: 18F-FDG PET Texture Analysis as Predictor of Patient Survival 2018; 8


